12 results about "Cellular biomarkers" patented technology

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).

The present invention provides a method for selecting a cancer patient for a cancer treatment or for predicting or monitoring the response of a cancer patient to a cancer treatment, comprising: determining the level of effector regulatory T cells in a biological sample from the patient, wherein said level of effector regulatory T cells correlates with the responsiveness of said patient to the cancer treatment.

The present invention relates to a urine sample stabilization protection solution and its application in biomarker detection, belonging to the technical field of application of urine in biomarker detection after storage and transportation at room temperature. The urine sample stabilization preservation solution is composed of physiological saline, preservatives, co-solvent stabilizers, inhibitor compositions and surfactants in a certain proportion; the inhibitor compositions are protease inhibitors, nuclease inhibitors and cell apoptosis inhibitors. The urine sample stabilization preservation solution is used for room temperature storage of urine samples, which can prevent the degradation of proteins, peptides and nucleic acids in urine under room temperature conditions, prevent enzyme inactivation, prevent cell lysis and inhibit the growth of microorganisms, maintain osmotic pressure and pH stability, and maintain the integrity and activity of cells and biomarkers; after adding the preservation solution, the urine sample is stored at room temperature for no less than 30 days to ensure the accuracy and reproducibility of marker detection.

This invention belongs to the field of cell detection technology, specifically involving the application of NR4A1 as an early biomarker for gamma-ray radiation. This invention discovers that in the early stage (2 hours) after gamma-ray radiation, the protein and mRNA levels of NR4A1 are significantly increased, exhibiting a radiation dose-dependent effect. NR4A1 can serve as a 2-hour biomarker for gamma-ray irradiated HeLa cells, allowing for the screening of cells irradiated for 2 hours, differentiating the duration of gamma-ray irradiation, and achieving early diagnosis of cellular gamma-ray radiation.

The invention aims to provide a method for separating and amplifying placenta decidua matrix cells in a perinatal period. The method comprises the following steps: adding decidua tissues into a culture medium A containing collagenase for digestion treatment; cleaning to obtain a cell suspension A, and sieving to obtain a cell suspension B; mixing the cell suspension B with a Ficoll solution, and carrying out primary gradient centrifugation; mixing the cell layer and the supernate layer with normal saline, and then carrying out secondary gradient centrifugation; and culturing the cell block mass and the culture medium B in an incubator. According to the method, the success rate of separation and amplification of the placenta decidua interstitial cells in the perinatal period can be increased, the separated and proliferated cells have group cell biomarker expression for tissue repair, and the separation technical method is improved, so that highly purified cells are obtained.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell- like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).

The invention relates to a biomarker of periapical cells and application of the biomarker, and belongs to the technical field of biological detection. The objective of the invention is to solve the problem that a conventional periodontal cell marker has expression overlap with other interstitial cells under an anoxic condition, cannot accurately distinguish tip periodontal cell subgroups, and hinders functional research and targeted therapy development thereof. The method comprises the following steps: screening 15 specific genes (including Adamts9, Cd93, Ctla2a, Fkbp1a, Angpt2 and the like) as periapical cell biomarkers by adopting machine learning according to brain single cell sequencing data of a high-altitude hypoxia mouse; and constructing a logistic regression prediction model to realize cell identification. According to the biomarker combination and the biomarker model, the false detection rate (lt; 5%). A new molecular marker for accurately identifying periapical cells is developed through a machine learning method based on a big data set, and a brand new breakthrough is provided for developing hypoxia response type periapical cell specific markers and functional targets.

The present invention discloses a biomarker and an application thereof. The biomarker is a cell expressing CD8+CD16++. The application of the biomarker is to use the biomarker to evaluate the immune aging of an organism. The organism is a human body.

The present invention provides diagnostic methods, therapeutic methods, and therapeutic compositions for lymphoma (e.g., diffuse large B-cell lymphoma (e.g., hair center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The present invention is based, at least in part, on the discovery that macrophage biomarkers can be used in methods for identifying, diagnosing, or predicting the efficacy of treatment with an anti-CD79b immunoconjugate (e.g., vipostuzumab) and an anti-CD20 antibody (e.g., ototuzumab or rituximab).

In various aspects, the present disclosure provides methods for detection of various cancer types, comprising measuring the level of target molecules in a sample. In some embodiments, the one or more target molecules include a cell-free DNA (cfDNA) from a plurality of different target genomic regions that are differentially methylated in at least one of a plurality of cancer, and a plurality of different polypeptides that are differentially expressed in at least one of the plurality of cancer types. Methods for training a classifier for detecting target molecules from a cancer are also provided.

The invention belongs to the technical field of cell extraction, and provides a bladder cancer stem cell biomarker extraction method, which comprises: in the historical extraction of bladder cancer stem cell biomarkers, obtaining a plurality of biomarker concentrations of each operation, then according to the biomarker concentrations, carrying out effective degree evaluation on each operation, constructing a historical feature library according to an evaluation result, performing extraction stability analysis on a plurality of biomarkers in the historical feature library to obtain a stability analysis result, and constructing a stable extraction feature library according to the stability analysis result, so that the extraction stability of the biomarkers is comprehensively analyzed from two dimensions of extraction times and extraction concentration; accurate data support is provided for screening and extracting biomarkers with high stability and bringing the biomarkers into a stable extraction feature library, the reliable stable extraction feature library is constructed, and more stable and accurate biomarker features are provided for subsequent application such as research and diagnosis.